What Ojemda’s JCA reveals about new era of clinical HTA in Europe

An analysis of GlobalData’s Drug Pricing (POLI) & HTA database shows no HTA outcome for Ojemda in the wake of the JCA review.

Source: Pharmaceutical Technology